Stem Cell Innovations in Heart Disease

In adults, evidence from randomized controlled trials has matured. A 2024 systematic review and meta-analysis pooling 17 randomized MSC trials demonstrated significant improvements in left ventricular ejection fraction (LVEF), ventricular volumes, and functional capacity, with no new safety concerns. However, heterogeneity in cell source, dosing, and delivery route limits universal conclusions [2].

The strongest signals appear when patient selection is refined. In the DREAM-HF trial, the largest sham-controlled MSC study to date, allogeneic mesenchymal precursor cells were delivered transendocardially. A post-hoc analysis reported in 2024 showed reduced major adverse cardiovascular events (MACE) over ≈30 months in ischaemic HFrEF patients with systemic inflammation (hsCRP ≥2 mg/L), supporting an anti-inflammatory mechanism [3]. These findings are clinically meaningful but require prospective validation in inflammation-selected populations before they inform practice.

Among perinatal sources, umbilical cord–derived MSCs (UC-MSCs), particularly from Wharton’s jelly, are especially promising due to their ready availability, low immunogenicity, and potent secretome. In the RIMECARD trial, a phase 1/2 randomized study, a single intravenous dose of UC-MSCs improved both LVEF and quality of life in patients with chronic heart failure [4]. A 2023 meta-analysis of UC-MSCs in cardiac disease reinforced safety and showed efficacy signals but stressed the need for standardized protocols and larger phase 2/3 trials [5]. Current research now explores multi-dose regimens; a U.S. clinical program is testing repeated infusions in chronic HF, marking the transition of UC-MSC therapy from exploratory to structured late-phase evaluation [6].

Cord blood–derived cells have been explored mainly in acute myocardial infarction and cardiomyopathies. Early-phase studies (e.g., NCT04056819) are evaluating intracoronary and intravenous delivery, but the evidence base is smaller and less mature compared to UC-MSCs [7].

The frontier of engineered heart muscle (EHM) derived from pluripotent stem cells has delivered a breakthrough. A 2025 Nature report documented large-scale myocardial remuscularization in primates and the first-in-human compassionate-use case within the BioVAT-HF program, without fatal arrhythmias and with rigorous molecular confirmation of safety [8]. While still experimental and requiring surgical delivery with immunosuppression, EHM represents the clearest step yet toward true myocardial replacement.

Another parallel innovation is extracellular vesicles (EVs), or exosomes, derived from MSCs. Between 2023 and 2025, multiple reviews and preclinical studies confirmed their anti-inflammatory and pro-angiogenic benefits, with novel delivery strategies such as hydrogels and patches improving local retention [9]. EV-based therapies are now entering first-in-human cardiovascular applications, potentially offering a scalable, cell-free alternative.

Paediatric Clinical Trials

In children, particularly those with congenital heart defects such as Hypoplastic Left Heart Syndrome (HLHS), regenerative approaches are being studied alongside surgical palliation. Currently, at least six clinical trials (Phase I–III) are investigating cord blood or MSC-based interventions in paediatric heart disease:

• Phase I trials: Autologous cord blood mononuclear cell (UCB-MNC) injections during Stage II repair in HLHS (safety and feasibility focus).
• Phase II trials: The Mayo Clinic’s AutoCell-II program, assessing intramyocardial UCB-MNCs during Glenn repair, and the ELPIS trial, testing donor MSCs during Glenn/Fontan surgery.
• Phase III trial: The APOLLON study, evaluating intracoronary cardiac stem cells during Stage II/III surgeries.

In addition, a systematic review identified 12 completed Phase I–II neonatal cell therapy trials (across cardiac, pulmonary, and neurological diseases) and 24 registered ongoing studies, with three specifically targeting congenital heart disease. Collectively, these studies demonstrate that paediatric regenerative cardiology is still in early-to-mid clinical stages but is steadily progressing from safety and feasibility (Phase I) toward efficacy testing (Phase II/III).

Conclusion

The clinical landscape underscores three key themes:

1. Adult HF: MSC therapy shows reproducible benefit in inflammation-enriched ischaemic populations, but late-phase confirmatory trials are essential.
2. Cord-derived therapies: UC-MSCs are the most advanced perinatal product in HF, with multiple trials now testing repeated dosing; cord blood–derived therapies remain earlier in development.
3. Paediatrics: Early-phase HLHS and congenital heart disease trials highlight the potential of cord blood and tissue stem cells in one of the most sensitive populations, with at least six trials across phases I–III already active.

Stem cell therapy for heart disease remains investigational, but both adult and paediatric studies show real momentum. With growing trial numbers and innovations in engineered tissues and EVs, regenerative cardiology is steadily moving toward clinical translation.